Zheng Quan Shi Bao Wang·2025-04-23 13:32Core Insights - Lijun Group reported a revenue of 3.181 billion yuan for Q1 2025, a year-on-year decrease of 1.92%, while net profit reached 637 million yuan, reflecting a year-on-year increase of 4.75% [1] - The growth in net profit marks a continued trend of stable growth for the company over several years [1] Product Performance - Key contributors to the company's performance include products for mental and gastrointestinal diseases [1] - In the mental health sector, Lijun Group has developed a product matrix covering common conditions such as schizophrenia and depression, with core products including Ruili (fluvoxamine) and Kanger (paliperidone), both recognized as first-line treatments in authoritative guidelines [1] - Additional products like Litingxin (bupropion), Shulida (lurasidone), and Ruisi Tuo (quetiapine) form a multi-target, multi-mechanism treatment network, providing personalized treatment options for patients with schizophrenia and bipolar disorder [1] Research and Development Pipeline - Lijun Group's R&D pipeline is characterized by a complete and well-structured approach in the mental health field [2] - The company is addressing difficult-to-treat conditions with innovative targets, such as NS-041, which shows promise for drug-resistant epilepsy and severe depression [2] - Long-acting formulations, including injectable aripiprazole microspheres and paliperidone palmitate, are being developed to improve patient compliance [2] - NS-041, a new generation KCNQ2/3 activator, is expected to enter Phase II clinical trials, with potential applications extending to severe depression, bipolar disorder, neuropathic pain, and amyotrophic lateral sclerosis [2] - The company anticipates approval for its significant schizophrenia treatment, aripiprazole microspheres, in the near future [2]